Correlates of serum hepcidin levels and its association with cardiovascular disease in an elderly general population

Clinical Chemistry and Laboratory Medicine

Volumn 54, Issue 1, 2016, Pages 151-161

  Pechlaner, Raimund ^a   Kiechl, Stefan ^a   Mayr, Manuel ^b   Santer, Peter ^c   Weger, Siegfried ^d   Haschka, David ^a   Bansal, Sukhvinder S ^e   Willeit, Johann ^a   Weiss, Günter ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c BRUNECK HOSPITAL   (Italy)

^d Hospital of Bruneck   (Italy)

^e KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

atherosclerosis; biomarkers; cardiovascular disease; hepcidin; iron metabolism

Indexed keywords

FERRITIN; FIBRINOGEN; GAMMA GLUTAMYLTRANSFERASE; HEMOGLOBIN; HEPCIDIN;

AGED; AGING; ALCOHOL CONSUMPTION; ARTICLE; BLOOD SAMPLING; CARDIOVASCULAR DISEASE; CAROTID ATHEROSCLEROSIS; CEREBROVASCULAR ACCIDENT; DIETARY INTAKE; DISEASE ASSOCIATION; FEMALE; FOOD FREQUENCY QUESTIONNAIRE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GROUPS BY AGE; HEALTH SURVEY; HEART INFARCTION; HEMOGLOBIN BLOOD LEVEL; HUMAN; INCIDENCE; INFECTION; IRON INTAKE; IRON STORAGE; MAJOR CLINICAL STUDY; MALE; PHYSICAL ACTIVITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SUDDEN CARDIAC DEATH; TANDEM MASS SPECTROMETRY; ULTRASOUND; AGE; BLOOD; METABOLISM; MIDDLE AGED; VERY ELDERLY;

AGE FACTORS; AGED; AGED, 80 AND OVER; AGING; CARDIOVASCULAR DISEASES; FEMALE; FERRITINS; FIBRINOGEN; GAMMA-GLUTAMYLTRANSFERASE; HEPCIDINS; HUMANS; MALE; MIDDLE AGED; TANDEM MASS SPECTROMETRY;

EID: 84954318517     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/cclm-2015-0068     Document Type: Article

References (49)

1. Ganz T. Systemic iron homeostasis. Physiol Rev 2013;93: 1721-41.
2. Hentze MW, Muckenthaler MU, Galy B, Camaschella C. Two to tango: regulation of mammalian iron metabolism. Cell 2010;142:24-38.
3. Sonnweber T, Nachbaur D, Schroll A, Nairz M, Seifert M, Demetz E, et al. Hypoxia induced downregulation of hepcidin is mediated by platelet derived growth factor BB. Gut 2014;63:1951-9.
4. Hou Y, Zhang S, Wang L, Li J, Qu G, He J, et al. Estrogen regulates iron homeostasis through governing hepatic hepcidin expression via an estrogen response element. Gene 2012;511:398-403.
5. Vecchi C, Montosi G, Zhang K, Lamberti I, Duncan SA, Kaufman RJ, et al. ER stress controls iron metabolism through induction of hepcidin. Science 2009;325:877-80.
6. Goodnough JB, Ramos E, Nemeth E, Ganz T. Inhibition of hepcidin transcription by growth factors. Hepatology 2012;56:291-9.
7. Latour C, Kautz L, Besson-Fournier C, Island M-L, Canonne-Hergaux F, Loréal O, et al. Testosterone perturbs systemic iron balance through activation of epidermal growth factor receptor signaling in the liver and repression of hepcidin. Hepatology 2014;59:683-94.
8. Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Donovan A, Ward DM, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 2004;306:2090-3.
9. Theurl I, Aigner E, Theurl M, Nairz M, Seifert M, Schroll A, et al. Regulation of iron homeostasis in anemia of chronic disease and iron deficiency anemia: diagnostic and therapeutic implications. Blood 2009;113:5277-86.
10. Sullivan JL. Iron in arterial plaque: A modifiable risk factor for atherosclerosis. Biochim Biophys Acta 2009;1790:718-23.
11. Kiechl S, Aichner F, Gerstenbrand F, Egger G, Mair A, Rungger G, et al. Body iron stores and presence of carotid atherosclerosis. Results from the Bruneck Study. Arterioscler Thromb Vasc Biol 1994;14:1625-30.
12. Kiechl S, Willeit J, Egger G, Poewe W, Oberhollenzer F. Body iron stores and the risk of carotid atherosclerosis prospective results from the Bruneck study. Circulation 1997;96:3300-7.
13. Saeed O, Otsuka F, Polavarapu R, Karmali V, Weiss D, Davis T, et al. Pharmacological suppression of hepcidin increases macrophage cholesterol efflux and reduces foam cell formation and atherosclerosis. Arterioscler Thromb Vasc Biol 2012;32:299-307.
14. Kautz L, Gabayan V, Wang X, Wu J, Onwuzurike J, Jung G, et al. Testing the iron hypothesis in a mouse model of atherosclerosis. Cell Rep 2013;5:1436-42.
15. Li JJ, Meng X, Si HP, Zhang C, Lv HX, Zhao YX, et al. Hepcidin destabilizes atherosclerotic plaque via overactivating macrophages after erythrophagocytosis. Arterioscler Thromb Vasc Biol 2012;32:1158-66.
16. Sullivan JL. Macrophage iron, hepcidin, and atherosclerotic plaque stability. Exp Biol Med 2007;232:1014-20.
17. Galesloot TE, Holewijn S, Kiemeney LA, de Graaf J, Vermeulen SH, Swinkels DW. Serum hepcidin is associated with presence of plaque in postmenopausal women of a general population. Arterioscler Thromb Vasc Biol 2014;34:446-56.
18. van der Weerd NC, Grooteman MP, Bots ML, van den Dorpel MA, den Hoedt CH, Mazairac AH, et al. Hepcidin-25 is related to cardiovascular events in chronic haemodialysis patients. Nephrol Dial Transplant 2013;28:3062-71.
19. Kuragano T, Itoh K, Shimonaka Y, Kida A, Furuta M, Kitamura R, et al. Hepcidin as well as TNF-α are significant predictors of arterial stiffness in patients on maintenance hemodialysis. Nephrol Dial Transplant 2011;26:2663-7.
20. Valenti L, Dongiovanni P, Motta BM, Swinkels DW, Bonara P, Rametta R, et al. Serum hepcidin and macrophage iron correlate with mcp-1 release and vascular damage in patients with metabolic syndrome alterations. Arterioscler Thromb Vasc Biol 2011;31:683-90.
21. Kiechl S, Lorenz E, Reindl M, Wiedermann CJ, Oberhollenzer F, Bonora E, et al. Toll-like receptor 4 polymorphisms and atherogenesis. N Engl J Med 2002;347:185-92.
22. Kiechl S, Wittmann J, Giaccari A, Knoflach M, Willeit P, Bozec A, et al. Blockade of receptor activator of nuclear factor-κB (RANKL) signaling improves hepatic insulin resistance and prevents development of diabetes mellitus. Nat Med 2013;19:358-63.
23. Willeit K, Pechlaner R, Egger G, Weger S, Oberhollenzer M, Willeit J, et al. Carotid atherosclerosis and incident atrial fibrillation. Arterioscler Thromb Vasc Biol 2013;33:2660-5.
24. Kiechl S, Schett G, Schwaiger J, Seppi K, Eder P, Egger G, et al. Soluble receptor activator of nuclear factor-κb ligand and risk for cardiovascular disease. Circulation 2007;116:385-91.
25. Bansal SS, Abbate V, Bomford A, Halket JM, Macdougall IC, Thein SL, et al. Quantitation of hepcidin in serum using ultrahigh-pressure liquid chromatography and a linear ion trap mass spectrometer. Rapid Commun Mass Spectrom 2010;24:1251-9.
26. Compendium of physical activities: an update of activity codes and MET intensities.
27. Kiechl S, Willeit J. The natural course of atherosclerosis. Part I: incidence and progression. Arterioscler Thromb Vasc Biol 1999;19:1484-90.
28. Willeit J, Kiechl S, Oberhollenzer F, Rungger G, Egger G, Bonora E, et al. Distinct risk profiles of early and advanced atherosclerosis: prospective results from the Bruneck Study. Arterioscler Thromb Vasc Biol 2000;20:529-37.
29. Nomenclature and criteria for diagnosis of ischemic heart disease. Report of the Joint International Society and Federation of Cardiology/World Health Organization task force on standardization of clinical nomenclature. Circulation 1979;59:607-9.
30. Walker AE, Robins M, Weinfeld FD. The National Survey of Stroke. Clinical findings. Stroke J Cereb Circ 1981;12 (2 Pt 2 Suppl 1):I13-44.
31. Koenker R, Hallock KF. Quantile regression. J Econ Perspect 2001;15:143-56.
32. Galesloot TE, Vermeulen SH, Geurts-Moespot AJ, Klaver SM, Kroot JJ, van Tienoven D, et al. Serum hepcidin: reference ranges and biochemical correlates in the general population. Blood 2011;117:e218-25.
33. den Elzen WP, de Craen AJ, Wiegerinck ET, Westendorp RG, Swinkels DW, Gussekloo J. Plasma hepcidin levels and anemia in old age. The Leiden 85-Plus Study. Haematologica 2013;98:448-54.
34. Kroot JJ, Kemna EH, Bansal SS, Busbridge M, Campostrini N, Girelli D, et al. Results of the first international round robin for the quantification of urinary and plasma hepcidin assays: need for standardization. Haematologica 2009;94:1748-52.
35. Traglia M, Girelli D, Biino G, Campostrini N, Corbella M, Sala C, et al. Association of HFE and TMPRSS6 genetic variants with iron and erythrocyte parameters is only in part dependent on serum hepcidin concentrations. J Med Genet 2011;48:629-34.
36. Schaap CC, Hendriks JC, Kortman GA, Klaver SM, Kroot JJ, Laarakkers CM, et al. Diurnal rhythm rather than dietary iron mediates daily hepcidin variations. Clin Chem 2013;59:527-35.
37. Kroot JJ, Hendriks JC, Laarakkers CM, Klaver SM, Kemna EH, Tjalsma H, et al. (Pre)analytical imprecision, between-subject variability, and daily variations in serum and urine hepcidin: implications for clinical studies. Anal Biochem 2009;389:124-9.
38. Ganz T, Olbina G, Girelli D, Nemeth E, Westerman M. Immunoassay for human serum hepcidin. Blood 2008;112:4292-7.
39. Pantopoulos K, Porwal SK, Tartakoff A, Devireddy L. Mechanisms of mammalian iron homeostasis. Biochemistry (Mosc) 2012;51:5705-24.
40. Thomas C, Kobold U, Balan S, Roeddiger R, Thomas L. Serum hepcidin-25 may replace the ferritin index in the Thomas plot in assessing iron status in anemic patients. Int J Lab Hematol 2011;33:187-93.
41. Weiss G, Theurl I, Eder S, Koppelstaetter C, Kurz K, Sonnweber T, et al. Serum hepcidin concentration in chronic haemodialysis patients: associations and effects of dialysis, iron and erythropoietin therapy. Eur J Clin Invest 2009;39:883-90.
42. Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med 2005;352:1011-23.
43. Busti F, Campostrini N, Martinelli N, Girelli D. Iron deficiency in the elderly population, revisited in the hepcidin era. Drug Metab Transp 2014;5:83.
44. Bode JG, Albrecht U, Häussinger D, Heinrich PC, Schaper F. Hepatic acute phase proteins-regulation by IL-6-and IL-1-type cytokines involving STAT3 and its crosstalk with NF-κB-dependent signaling. Eur J Cell Biol 2012;91: 496-505.
45. Poli M, Girelli D, Campostrini N, Maccarinelli F, Finazzi D, Luscieti S, et al. Heparin: A potent inhibitor of hepcidin expression in vitro and in vivo. Blood 2011;117:997-1004.
46. Zmijewski E, Lu S, Harrison-Findik DD. TLR4 signaling and the inhibition of liver hepcidin expression by alcohol. World J Gastroenterol 2014;20:12161-70.
47. Fleming DJ, Tucker KL, Jacques PF, Dallal GE, Wilson PW, Wood RJ. Dietary factors associated with the risk of high iron stores in the elderly Framingham Heart Study cohort. Am J Clin Nutr 2002;76:1375-84.
48. Theurl I, Schroll A, Nairz M, Seifert M, Theurl M, Sonnweber T, et al. Pathways for the regulation of hepcidin expression in anemia of chronic disease and iron deficiency anemia in vivo. Haematologica 2011;96:1761-9.
49. Vecchi C, Montosi G, Garuti C, Corradini E, Sabelli M, Canali S, et al. Gluconeogenic signals regulate iron homeostasis via hepcidin in mice. Gastroenterology 2014;146:1060-9.e3.